HC Wainwright Reiterates Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday, Marketbeat.com reports. They currently have a $73.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 61.01% from the company’s current price. […]
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday, Marketbeat.com reports. They currently have a $73.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 61.01% from the company’s current price. […]
